阿斯巴拉金:在向瘤治疗中的一个关键代谢结点
Xuan Wang1, Weijian Gong1, Xueyou Xiong1
1Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, Nanjing 210004, China.
Pharmacological research
|July 13, 2024
概括
瘤细胞依赖阿斯巴拉金来生长,使其限制成为潜在的癌症治疗方法. 向瘤适应机制可以克服转基因癌症的耐药性.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
背景情况:
- 瘤微环境中的营养生物可用性对癌症进展至关重要.
- 谷氨酸及其代谢物阿斯巴拉金对于瘤细胞的增殖和生存至关重要.
- 阿斯巴拉金枯竭是一种经过验证的治疗策略,特别是在急性淋巴细胞白血病 (ALL) 中.
研究的目的:
- 审查阿斯巴拉金的来源及其在瘤进展中的作用.
- 探索限制阿斯巴拉金的生物可用性如何影响特定的转基因瘤.
- 确定针对瘤适应阿斯巴拉金限制的治疗策略,以克服耐药性.
主要方法:
- 关于阿斯巴拉金代谢及其对癌症的影响的文献综述.
- 对瘤细胞适应阿斯巴拉金缺乏机制的分析.
- 探索参与阿斯巴拉金限制抵抗的信号通路.
主要成果:
- 瘤细胞可以适应阿斯巴拉金的限制,影响治疗的疗效.
- 对阿斯巴拉金限制的敏感化和适应机制在基因改变的瘤之间有所不同.
- 阿斯巴拉金的来源及其利用在不同类型的癌症中各不相同.
结论:
- 准阿斯帕拉金的生物可用性是癌症治疗的一个有希望的策略.
- 了解瘤适应途径对于提高治疗结果至关重要.
- 通过向阿斯巴拉金代谢来开发基因改变癌症的精确疗法是可行的.
关键词:
阿斯巴拉金酶 (Pubchem CID: 436058) 是一种亚斯巴拉基因 (Aspragine) 是一种阿斯巴拉金合成酶 (普克姆CID: 381121140) 是一种酸 (Pubchem CID: 5960) 是一种癌症 癌症 癌症 癌症基因变异是一种基因变异.谷氨酸 (Pubchem CID: 33032) 的使用情况谷氨胺酶 (Pubchem CID: 72950407) 的使用情况谷氨胺 (Pubchem CID: 5961) 的使用情况希斯蒂丁 (Pubchem CID: 6274) 是一种亚斯巴拉金 (L-亚斯巴拉金) (普克姆公司 CID: 6267)代谢过程中的代谢.赛林 (Pubchem CID: 5951) 是一个有针对性的治疗.氨酸 (Pubchem CID: 6288) 的使用情况.更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
28.2K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
